132 related articles for article (PubMed ID: 34564893)
1. Sex differences in the Norwegian Tenecteplase Trial (NOR-TEST).
Ihle-Hansen H; Sandset EC; Ihle-Hansen H; Hagberg G; Thommessen B; Rønning OM; Kvistad CE; Novotny V; Naess H; Waje-Andreassen U; Thomassen L; Logallo N
Eur J Neurol; 2022 Feb; 29(2):609-614. PubMed ID: 34564893
[TBL] [Abstract][Full Text] [Related]
2. Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
Zhong CS; Beharry J; Salazar D; Smith K; Withington S; Campbell BCV; Wilson D; Le Heron C; Mason D; Duncan R; Reimers J; Mein-Smith F; Diprose WK; Barber PA; Ranta A; Fink JN; Wu TY
Stroke; 2021 Mar; 52(3):1087-1090. PubMed ID: 33588597
[TBL] [Abstract][Full Text] [Related]
3. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
Roaldsen MB; Eltoft A; Wilsgaard T; Christensen H; Engelter ST; Indredavik B; Jatužis D; Karelis G; Kõrv J; Lundström E; Petersson J; Putaala J; Søyland MH; Tveiten A; Bivard A; Johnsen SH; Mazya MV; Werring DJ; Wu TY; De Marchis GM; Robinson TG; Mathiesen EB;
Lancet Neurol; 2023 Feb; 22(2):117-126. PubMed ID: 36549308
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
[TBL] [Abstract][Full Text] [Related]
6. Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase.
Kim DJ; Singh N; Catanese L; Yu AYX; Demchuk AM; Lloret-Villas MI; Deschaintre Y; Coutts SB; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Manosalva H; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Phillips S; Hill MD; Poppe AY; Ademola A; Shamy M; Bala F; Sajobi TT; Swartz RH; Almekhlafi MA; Menon BK; Field TS
Stroke; 2024 Feb; 55(2):288-295. PubMed ID: 38174568
[TBL] [Abstract][Full Text] [Related]
7. Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST).
Kvistad CE; Novotny V; Næss H; Hagberg G; Ihle-Hansen H; Waje-Andreassen U; Thomassen L; Logallo N
Int J Stroke; 2019 Jul; 14(5):508-516. PubMed ID: 30019629
[TBL] [Abstract][Full Text] [Related]
8. Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial.
Sajobi TT; Arimoro OI; Ademola A; Singh N; Bala F; Almekhlafi MA; Deschaintre Y; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz GJ; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JS; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra SM; Gioia LC; Jalini S; Cayer C; Phillips SJ; Elamin E; Shoamanesh A; Subramaniam S; Kate MP; Jacquin G; Camden MC; Benali F; Alhabli I; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe AY; Sehgal A; Zhang Q; Lethebe B; Doram C; Shamy M; Kenney C; Buck BH; Swartz RH; Menon BK
Stroke; 2024 Mar; 55(3):524-531. PubMed ID: 38275116
[TBL] [Abstract][Full Text] [Related]
9. Tenecteplase, 0.4 mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR-TEST and NOR-TEST 2A.
Novotny V; Kvistad CE; Naess H; Logallo N; Fromm A; Khanevski AN; Thomassen L
J Am Heart Assoc; 2023 Oct; 12(20):e030320. PubMed ID: 37830342
[TBL] [Abstract][Full Text] [Related]
10. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Zhao H; Alemseged F; Ng F; Bailey P; Rice H; de Villiers L; Dewey HM; Choi PMC; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Kraemer T; Krause M; Cordato D; Field D; Ma H; O'Brien B; Clissold B; Miteff F; Clissold A; Cloud GC; Bolitho LE; Bonavia L; Bhattacharya A; Wright A; Mamun A; O'Rourke F; Worthington J; Wong AA; Levi CR; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM;
JAMA; 2020 Apr; 323(13):1257-1265. PubMed ID: 32078683
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and predictors of stroke mimics in young patients in the norwegian tenecteplase stroke trial (NOR-TEST).
Jacobsen E; Logallo N; Kvistad CE; Thomassen L; Idicula T
BMC Neurol; 2023 Nov; 23(1):406. PubMed ID: 37968581
[TBL] [Abstract][Full Text] [Related]
12. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
[TBL] [Abstract][Full Text] [Related]
13. Switching to Tenecteplase for Stroke Thrombolysis: Real-World Experience and Outcomes in a Regional Stroke Network.
Mahawish K; Gommans J; Kleinig T; Lallu B; Tyson A; Ranta A
Stroke; 2021 Oct; 52(10):e590-e593. PubMed ID: 34465202
[TBL] [Abstract][Full Text] [Related]
14. Tenecteplase versus alteplase after acute ischemic stroke at high age.
Thommessen B; Næss H; Logallo N; Kvistad CE; Waje-Andreassen U; Ihle-Hansen H; Ihle-Hansen H; Thomassen L; Morten Rønning O
Int J Stroke; 2021 Apr; 16(3):295-299. PubMed ID: 32631157
[TBL] [Abstract][Full Text] [Related]
15. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Dewey HM; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Ang T; Miteff F; Levi CR; Rodrigues E; Zhao H; Salvaris P; Garcia-Esperon C; Bailey P; Rice H; de Villiers L; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Wong AA; Muller C; Coulthard A; Mitchell K; Clouston J; Mahady K; Field D; Ma H; Phan TG; Chong W; Chandra RV; Slater LA; Krause M; Harrington TJ; Faulder KC; Steinfort BS; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM;
N Engl J Med; 2018 Apr; 378(17):1573-1582. PubMed ID: 29694815
[TBL] [Abstract][Full Text] [Related]
16. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study.
Campbell BC; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Yan B; Thijs V; Desmond PM; Parsons MW; Donnan GA; Davis SM
Int J Stroke; 2020 Jul; 15(5):567-572. PubMed ID: 31564231
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and safety profile of Tenecteplase in wake-up stroke.
Ahmed HK; Logallo N; Thomassen L; Novotny V; Mathisen SM; Kurz MW
Acta Neurol Scand; 2020 Nov; 142(5):475-479. PubMed ID: 32511749
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
Parsons M; Spratt N; Bivard A; Campbell B; Chung K; Miteff F; O'Brien B; Bladin C; McElduff P; Allen C; Bateman G; Donnan G; Davis S; Levi C
N Engl J Med; 2012 Mar; 366(12):1099-107. PubMed ID: 22435369
[TBL] [Abstract][Full Text] [Related]
19. Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale.
Rønning OM; Logallo N; Thommessen B; Tobro H; Novotny V; Kvistad CE; Aamodt AH; Næss H; Waje-Andreassen U; Thomassen L
Stroke; 2019 Feb; 50(2):498-500. PubMed ID: 30602354
[TBL] [Abstract][Full Text] [Related]
20. Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings.
George M; Baby N; Paul R; Zabeer M; Thomas C
J Clin Neurosci; 2021 Sep; 91():299-305. PubMed ID: 34373043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
